# ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

> **NCT04843761** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 473 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Remdesivir
- **DRUG:** Remdesivir Placebo
- **BIOLOGICAL:** Aviptadil
- **DRUG:** Aviptadil Placebo
- **DRUG:** Corticosteroid

## Key facts

- **NCT ID:** NCT04843761
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-20
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-11-20
- **Target enrollment:** 473 (ACTUAL)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04843761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04843761, "ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04843761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*